Search:
   

Wednesday, October 11, 2017

Equity Corporate Actions Alert #2017 - 49
(UPDATED) Information Regarding the Acquisition of SciClone Pharmaceuticals, Inc. (SCLN)

Category:

  • Industry Announcement

Markets Impacted:

Contact Information:

Resources:

At a special meeting on September 27, 2017, shareholders of SciClone Pharmaceuticals, Inc. (SCLN) approved an acquisition by entities affiliated with GL Capital Management GP Limited. The closing was completed today, October 13, 2017. The details are as follows:

Company Name: SciClone Pharmaceuticals, Inc.
Issue: Common Stock
CUSIP#: 80862K104
Symbol: SCLN
Marketplace Effective Date for Suspension: October 16, 2017
Merger Consideration: $11.18 per share

Please follow Nasdaq on Facebook RSS and Twitter.

Nasdaq (Nasdaq: NDAQ) is a leading global provider of trading, clearing, exchange technology, listing, information and public company services. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 90 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to approximately 3,900 total listings with a market value of approximately $13 trillion. To learn more, visit: business.nasdaq.com.

View NASDAQTrader.com Mobile